About Bioskryb
Bioskryb is a company based in Durham (United States) founded in 2018 by Jay West and Charles Gawad. Bioskryb has raised $11.5 million across 1 funding round from investors including Wilson Sonsini Goodrich & Rosati and Anzu Partners. The company has 21 employees. Bioskryb offers products and services including ResolveOME, BaseJumper, and ResolveDNA. Bioskryb operates in a competitive market with competitors including Nanopore, PacBio, Omniome, Complete Genomics and QuantuMDx, among others.
- Headquarter Durham, United States
- Employees 21
- Founders Jay West, Charles Gawad
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bioskryb.com
- Social LinkedIn X Facebook
- Legal Name Bioskryb Genomics, Inc.
- Total Equity Funding$11.5M (USD)
in 1 rounds
- Latest Funding Round$11.5M (USD), Seed
Jan 2020
- InvestorsWilson Sonsini Goodrich & Rosati
& 1 more
- Employee Count21
Products & Services of Bioskryb
Bioskryb offers a comprehensive portfolio of products and services, including ResolveOME, BaseJumper, and ResolveDNA.
Amplifies genome and transcriptome from single cells for integrated analysis.
Visualizes single-cell genomics data for molecular discovery insights.
Enables high genome recovery and variant detection in single-cell research.
Funding Insights of Bioskryb
Bioskryb has successfully raised a total of $11.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $11.5 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.5M
- Total Rounds 1
- Last Round Seed — $11.5M
- First Round $11.5M
(Jan 2020)
- Investors Count 2
All 1 funding rounds of Bioskryb with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $11.5M | Seed | – | Anzu Partners |
2 investors in total: 2 institutional.
Investors in Bioskryb
Bioskryb has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Wilson Sonsini Goodrich & Rosati and Anzu Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in industrial and life sciences technology companies. | – | anzupartners.com | Washington, Dc, United States | |
Provider of legal services to technology and life science companies | 1961 | wsgr.com | Palo Alto, United States |
Investor details for Bioskryb
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bioskryb
26 people are tracked at Bioskryb (9 in leadership, 7 in board & advisors, 10 in team); the tracked headcount is 21.
| Name | Role | Group |
|---|---|---|
Jay West | Co-Founder & CEO | Leadership |
Charles Gawad | Co-Founder | Leadership |
Phyll Arrington | Director of Marketing, BioSkryb Genomics | Leadership |
Jeff Blackinton | Vice President Of Products & Services | Leadership |
Jennipher Jess | Digital Marketing Director | Leadership |
Magda Grabowska, PhD | Senior Director - Scientific Engagement | Leadership |
Suresh Pisharody | CEO | Leadership |
Rob Kaizerman | COO | Leadership |
Harsha K. | Senior Director, Commercial Operations | Leadership |
Mya Thomae | Scientific Advisor | Board & advisors |
Michael B. Kastan | Scientific Advisor | Board & advisors |
William E. Evans | Director & Scientific Advisor | Board & advisors |
Stefan M. Pfister | Scientific Advisor | Board & advisors |
Barry Behr | Scientific Advisor | Board & advisors |
David Michael | Director | Board & advisors |
Peter Park | Scientific Advisor | Board & advisors |
Caroline Hunter Tomblin | Senior Development Scientist | Team |
Durga Manjari Arvapalli | Scientist | Team |
Miranda Wilson Graybill | Sales Manager - West | Team |
Stephanie Scherer, PhD | Manager of Scientific Engagement | Team |
6 more people are available in the full profile.
Complete people profiles for Bioskryb
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bioskryb
2 dated milestones of Bioskryb across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Bioskryb is founded.
- Funding First funding round of $11.5M.
Competitors of Bioskryb
Bioskryb operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nanopore, PacBio, Omniome, Complete Genomics and QuantuMDx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nanoporetech.com | 2005 | Oxford, United Kingdom | $1.26B | 705 | Nanopore-based electronic systems for single-molecule analysis are developed. | |
| pacb.com | 2004 | Menlo Park, United States | $395M | 649 | Instrument systems and software for single-molecule real-time sequencing are developed. | |
| omniome.com | 2013 | San Diego, United States | $160.23M | 164 | Genome sequencing platform is provided for clinical diagnostics. | |
| completegenomics.com | 2006 | San Jose, United States | $124.99M | 70 | DNA sequencing platform for human genome analysis is developed. | |
| quantumdx.com | 2008 | Newcastle Upon Tyne, United Kingdom | $57.26M | 98 | Handheld diagnostic and sequencing devices are developed for personalized healthcare. | |
| bionano.com | 2002 | San Diego, United States | $124.2M | – | Provider of genome analysis solutions to researchers and clinicians | |
| genapsys.com | 2010 | Redwood, United States | $313.03M | 60 | Provider of DNA sequencing technologies for applied genomic testing and medical sequencing | |
| alveotechnologies.com | 2014 | Alameda, United States | $63.61M | – | Cloud-powered POC MDx device | |
| purigenbio.com | 2012 | Pleasanton, United States | $88.32M | 24 | Isotachophoresis technology is provided for nucleic acid sample preparation. | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems |
Detailed competitors of Bioskryb
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bioskryb
The website of Bioskryb (bioskryb.com) receives about 4.4K visits a month.
- Monthly visits4.4K
▼ 30.8% vs previous month
Latest news on Bioskryb
Complete news archive for Bioskryb
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Bioskryb
10 companies that operate in the same segment as Bioskryb (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Bioskryb
Bioskryb was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Bioskryb is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Jay West is the current CEO of Bioskryb. They have also founded this company.
Bioskryb is a funded company, having raised a total of $11.5M across 1 funding round to date. The company's 1st funding round was a Seed of $11.5M, raised on Jan 2020.
Bioskryb has 21 employees.
BioSkryb has developed a genome amplification system for cellular heterogeneity. The SkrybAmp technology performs Primary Template Directed Amplification (PTA) is used for base calling DNA sequencing. The features of the technology are it can control the amplicon size for adding Barcode identifiers to detect DNA lesions. The technology is applied in ancestry genotyping, gene editing accuracy determination, and detection of single resistant mutant cells (MRD) in cancers.
Bioskryb offers ResolveOME, BaseJumper, and ResolveDNA.
Bioskryb has 2 investors. Key investors include Wilson Sonsini Goodrich & Rosati, and Anzu Partners.
Bioskryb operates through Bioskryb Genomics, Inc..